Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus NIPS for Gastric Cancer with Positive Peritoneal Cytology
NCT05410847Phase 2Unknown
- Sponsor
- Hebei Medical University
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab in gastric cancer (GC), sponsored by Hebei Medical University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05410847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410847.